Abstract
Context: Molecular alterations in premalignant lesions of oral cavity are not well known, many reports and have found increased HER2 expression to be correlated with poor prognosis in oral cancer. However,literature on expression of HER2 in premalignant lesions is limited and data is conflicting in nature. Overexpression of HER2 in premalignant lesions may denote its positive contribution in malignant transformation of these lesions. Aims: To evaluate the expression of HER2 in premalignant lesions of oral cavity. Settings and Design: In this prospective observational study of 2 months, patients attending OPD at Department of ENT and meeting the inclusion criteria were included. Methods and Material: 23 samples of Leukoplakia and 1 sample of oral lichen planus were stained by routine H&E to confirm clinical diagnosis and assess dysplasia if any, 5 samples of normal mucosa were used as control. Immunohistochemical staining for HER2 was done. ASCO/CAP 2018 guidelines were used for reporting the results. Statistical analysis used: Percentage of lesions expressing cytoplasmic or membranous expression was calculated. Results: 1 sample of Leukoplakia with severe dysplasia expressed focal membranous staining. 20% leukoplakia lesions expressed cytoplasmic staining. Staining was not observed in oral lichen planus and leucoplakia without dysplasia. Conclusions: Membranous expression in Severe dysplasia and higher expression in oral cancer is in concordance with the multistep theory of carcinogenesis. Larger studies are needed if HER2 is to be proposed as a marker for oral premalignant lesions. Significance of cytoplasmic staining in oral premalignant lesions needs to be elucidated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by Indian council of medical research STS scheme vide reference number 2019-05752
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB, Dr.Baba saheb ambedkar medical college and hospital approved the prohject on 15 Feb 2019. The proposal was also approved under ICMR STS scheme ( ref number- 2019-05752)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article.
